Lyell Immunopharma - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeLyell Immunopharma
Lyell Immunopharma logo

Lyell Immunopharma

0 followers

LYEL

Performance

About Lyell Immunopharma

Lyell Immunopharma is a biotechnology company specializing in next-generation T-cell reprogramming technologies to enable durable CAR-T cell therapies for cancer. It operates as a fully integrated biopharma company focusing on immuno-oncology and developing therapies for hematologic malignancies and solid tumors, with manufacturing capabilities through its LyFE Manufacturing Center. The company emphasizes scientific innovation across its science, pipeline, and cell therapies, aiming to deliver transformative treatments for patients globally. Lyell is based in the United States with locations in South San Francisco, Seattle, and Bothell, Washington.

Recent News

No recent news for this company.

Recent Deals

No recent deals for this company.

Key Team Members

Stan Riddell, M.D.

Founder

Lynn Seely, M.D.

President and Chief Executive Officer

Crystal Mackall, M.D.

Founder

Ann Tomlin, M.S.

Chief Human Resource Officer

Jarrad Aguirre, M.D., M.B.A

Senior Vice President, Medical Affairs

Key Facts

HQ Location

South San Francisco, United States

Founded

2018

Employees

201 - 500

Status

Public

Website

https://lyell.com